MX375718B - [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. - Google Patents
[9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.Info
- Publication number
- MX375718B MX375718B MX2017010062A MX2017010062A MX375718B MX 375718 B MX375718 B MX 375718B MX 2017010062 A MX2017010062 A MX 2017010062A MX 2017010062 A MX2017010062 A MX 2017010062A MX 375718 B MX375718 B MX 375718B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods relating
- compositions
- isoquinolin
- pyrido
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- WMUDEMBOOGSKRP-UHFFFAOYSA-N [9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methanol Chemical compound COC=1C=C2CCN3C(C2=CC=1OC)CC(C(C3)CC(C)C)CO WMUDEMBOOGSKRP-UHFFFAOYSA-N 0.000 title 1
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 abstract 2
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113316P | 2015-02-06 | 2015-02-06 | |
| PCT/US2016/016892 WO2016127133A1 (en) | 2015-02-06 | 2016-02-05 | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010062A MX2017010062A (es) | 2017-11-01 |
| MX375718B true MX375718B (es) | 2025-03-06 |
Family
ID=55404854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010062A MX375718B (es) | 2015-02-06 | 2016-02-05 | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9714246B2 (https=) |
| EP (1) | EP3253752B1 (https=) |
| JP (1) | JP6755254B2 (https=) |
| KR (1) | KR102586138B1 (https=) |
| CN (1) | CN107438606B (https=) |
| AU (1) | AU2016215033B2 (https=) |
| CA (1) | CA2974540C (https=) |
| ES (1) | ES2960717T3 (https=) |
| IL (1) | IL253704B (https=) |
| MX (1) | MX375718B (https=) |
| RU (1) | RU2736509C2 (https=) |
| WO (1) | WO2016127133A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112642A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| CA2974540C (en) | 2015-02-06 | 2023-09-26 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| MY193767A (en) | 2015-10-30 | 2022-10-27 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| CN108925135B (zh) | 2015-12-23 | 2025-09-19 | 纽罗克里生物科学有限公司 | 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法 |
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| ES3024958T3 (en) | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| EP3860599B1 (en) | 2018-10-04 | 2024-05-15 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| PT4168409T (pt) | 2021-03-22 | 2025-06-12 | Neurocrine Biosciences Inc | Inibidores de vmat2 e métodos de utilização |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54125699A (en) | 1978-03-17 | 1979-09-29 | Nippon Chemiphar Co Ltd | Preparation of ( ) dihydroprotoemetine |
| RU2339636C2 (ru) * | 2003-06-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг | Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv) |
| PL2081929T3 (pl) * | 2006-11-08 | 2013-06-28 | Neurocrine Biosciences Inc | Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania |
| RU2339363C2 (ru) | 2006-12-28 | 2008-11-27 | Лидия Ибрагимовна Гайсанова | Мазь "бунхо", обладающая противовоспалительным и регенерирующим действием |
| NZ760790A (en) * | 2014-02-07 | 2022-11-25 | Neurocrine Biosciences Inc | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| CA2974540C (en) | 2015-02-06 | 2023-09-26 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
-
2016
- 2016-02-05 CA CA2974540A patent/CA2974540C/en active Active
- 2016-02-05 MX MX2017010062A patent/MX375718B/es active IP Right Grant
- 2016-02-05 US US15/017,480 patent/US9714246B2/en active Active
- 2016-02-05 JP JP2017541333A patent/JP6755254B2/ja active Active
- 2016-02-05 ES ES16705684T patent/ES2960717T3/es active Active
- 2016-02-05 EP EP16705684.5A patent/EP3253752B1/en active Active
- 2016-02-05 KR KR1020177024606A patent/KR102586138B1/ko active Active
- 2016-02-05 RU RU2017130514A patent/RU2736509C2/ru active
- 2016-02-05 WO PCT/US2016/016892 patent/WO2016127133A1/en not_active Ceased
- 2016-02-05 AU AU2016215033A patent/AU2016215033B2/en active Active
- 2016-02-05 CN CN201680008945.5A patent/CN107438606B/zh active Active
-
2017
- 2017-06-19 US US15/627,145 patent/US9988382B2/en active Active
- 2017-07-27 IL IL253704A patent/IL253704B/en active IP Right Grant
-
2018
- 2018-04-30 US US15/967,187 patent/US20180273533A1/en not_active Abandoned
-
2020
- 2020-01-22 US US16/748,999 patent/US11053242B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017010062A (es) | 2017-11-01 |
| ES2960717T3 (es) | 2024-03-06 |
| CN107438606A (zh) | 2017-12-05 |
| CA2974540C (en) | 2023-09-26 |
| US20200262834A1 (en) | 2020-08-20 |
| BR112017016934A2 (pt) | 2018-04-03 |
| US11053242B2 (en) | 2021-07-06 |
| IL253704A0 (en) | 2017-09-28 |
| RU2736509C2 (ru) | 2020-11-17 |
| US20170349586A1 (en) | 2017-12-07 |
| RU2017130514A3 (https=) | 2019-08-27 |
| CN107438606B (zh) | 2020-09-18 |
| AU2016215033A1 (en) | 2017-08-10 |
| RU2017130514A (ru) | 2019-03-07 |
| EP3253752C0 (en) | 2023-08-16 |
| NZ733899A (en) | 2024-01-26 |
| JP2018504437A (ja) | 2018-02-15 |
| US20160289226A1 (en) | 2016-10-06 |
| WO2016127133A1 (en) | 2016-08-11 |
| US9714246B2 (en) | 2017-07-25 |
| JP6755254B2 (ja) | 2020-09-16 |
| KR102586138B1 (ko) | 2023-10-05 |
| US9988382B2 (en) | 2018-06-05 |
| CA2974540A1 (en) | 2016-08-11 |
| EP3253752A1 (en) | 2017-12-13 |
| EP3253752B1 (en) | 2023-08-16 |
| IL253704B (en) | 2021-02-28 |
| AU2016215033B2 (en) | 2020-06-25 |
| KR20170113620A (ko) | 2017-10-12 |
| US20180273533A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375718B (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| MX2009004910A (es) | Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. | |
| MY204421A (en) | Pyruvate kinase activators for use in treating blood disorders | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| PH12019502263A1 (en) | Piperidines as covalent menin inhibitors | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| PH12015501813A1 (en) | Monocyclic pyridine derivative | |
| MX2020002824A (es) | Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia. | |
| MX378932B (es) | Triazoles sustituidos y métodos relacionados a estos. | |
| GEP20237476B (en) | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors | |
| MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
| MX2021004280A (es) | Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| MX356759B (es) | Derivados de pirimidinona como agentes antimalaricos. | |
| MX2016004963A (es) | Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |